CRISPR ‘gone wild’ has made stocks swoon, but studies show how to limit off-target editing
By Sharon Begley,
Stat News
| 03. 05. 2018
The fear that CRISPR-based genome repair for preventing or treating genetic diseases will be derailed by “editing gone wild” has begun to abate, scientists who are developing the technique say. Although there are still concerns that CRISPR might run amok inside patients and cause dangerous DNA changes, recent advances suggest that the risk is not as high as earlier research suggested and that clever molecular engineering can minimize it.
“Progress is being made at a pretty stunning rate,” said biochemist David Liu, of Harvard University and the Broad Institute, who has developed several versionsof CRISPR. A parade of new discoveries, he said, “suggests that it’s possible to use these genome-editing tools and not make unintended edits.”
The basic reason for such “off-target effects” is that CRISPR’s guide molecule, which is usually 20 genetic letters long, isn’t as precise as often advertised. Although it’s supposed to lead the DNA-cutting enzyme (the other principle component of CRISPR) to regions of the genome with those exact 20 letters, in practice it’s happy to find regions with just 18 or even fewer —...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...